Effect of Rifampicin on the Pharmacokinetics of Evogliptin in Healthy Volunteers.

Rifampicin decreased the AUC of evogliptin by 61.8% without significantly affecting C. The mechanism underlying the decrease in AUC is thought to be the induction of cytochrome P450 (CYP), especially 3A, by rifampicin. The adverse events, none of which were serious, were not significantly altered by the concomitant administration of evogliptin and rifampicin. Nevertheless, it would be prudent that evogliptin dosing should be carefully considered when co-administered with CYP3A inducers.